Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Non-Radiographic Axial Spondyloarthritis Therapeutic Industry By The Forecast Year 2029?
The market size for non-radiographic axial spondyloarthritis therapeutics has seen substantial growth in recent years. It is anticipated to increase from $0.93 billion in 2024 to $1.04 billion in 2025, progressing at a compound annual growth rate (CAGR) of 10.9%. The expansion observed historically is largely due to the rising prevalence of axial spondyloarthritis, enhancements in awareness coupled with a growing patient population, the increasing understanding of the disease propelling market development, an uptick in research and development efforts, and the wider acceptance of biologic therapies.
The non-radiographic axial spondyloarthritis therapeutic market size is projected to experience swift expansion in the coming years. This market is forecasted to reach $1.55 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.7%. Several factors are expected to drive this growth during the forecast period, including heightened awareness and prompt diagnosis, the proliferation of biosimilars, sustained progress in biologics alongside emerging therapeutic alternatives, a continuous rise in research and development endeavors, the increasing embrace of targeted and individualized treatments, and enhanced healthcare infrastructure. Key trends anticipated in this period encompass tailored treatment algorithms, the incorporation of digital instruments for diagnosis, a move towards treat-to-target (T2T) methodologies, value-based pricing frameworks, and the uptake of multidisciplinary management strategies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24627&type=smp
What Are The Main Drivers Boosting The Non-Radiographic Axial Spondyloarthritis Therapeutic Industry’s Expansion?
The non-radiographic axial spondyloarthritis therapeutic market is projected to experience growth, propelled by the rising number of clinical trials. These trials represent human research studies carried out to evaluate the safety, effectiveness, and adverse effects of medical treatments or interventions. The increase in clinical trials stems from a growing need for tailored and innovative therapies, which require rigorous assessment for their safety and efficacy. Clinical trials provide support for non-radiographic axial spondyloarthritis therapeutics by delivering evidence-based confirmation of treatment effectiveness and safety during the early stages of the disease, thus guiding regulatory approvals and integration into clinical practice. As an illustration, in November 2023, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported a 15% surge in annual recruitment for industry clinical trials within the UK, with participant figures climbing from 36,722 in 2021-22 to 42,088 in 2022-23. Therefore, the expanding clinical trial landscape is a significant driver of the non-radiographic axial spondyloarthritis therapeutic market’s growth.
What Are The Segment Types Shaping The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
The non-radiographic axial spondyloarthritis therapeutic market covered in this report is segmented –
1) By Type: Non-Steroidal Anti-Inflammatory Drugs, Biologics, Small Molecule Therapies, Corticosteroids
2) By Application: Oral, Injectable, Topical
3) By End User: Hospitals, Ambulatory Surgical Centers, Homecare Settings
Subsegments:
1) By Non-Steroidal Anti-Inflammatory Drugs: COX-2 Inhibitors, Non-Selective NSAIDs
2) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-17 (IL-17) Inhibitors
3) By Small Molecule Therapies: Janus Kinase (JAK) Inhibitors, Phosphodiesterase-4 (PDE4) Inhibitors
4) By Corticosteroids: Oral Corticosteroids, Intra-Articular Corticosteroid Injections
Which Market Trends Are Creating New Opportunities In The Non-Radiographic Axial Spondyloarthritis Therapeutic Industry?
Leading companies in the non-radiographic axial spondyloarthritis (nr-axSpA) therapeutic market are concentrating on securing regulatory approvals. This strategy aims to broaden their market reach, expedite the introduction of new treatments, and gain competitive advantages. Regulatory approvals signify official permission granted by government bodies, allowing a drug or therapy to be legally sold and prescribed after its safety, efficacy, and adherence to relevant standards have been established. For example, in October 2022, AbbVie Inc., a US-based biopharmaceutical firm, obtained FDA approval for Rinvoq (upadacitinib) to treat adults with active non-radiographic axial spondyloarthritis (nr-axSpA) who exhibit objective signs of inflammation and have not responded adequately to TNF inhibitors. This marks Rinvoq’s sixth U.S. indication and positions it as the first and only oral JAK inhibitor approved for nr-axSpA. The approval is founded on data from the SELECT-AXIS 2 clinical trial, where nearly half of the patients treated with Rinvoq showed significant betterment in disease activity compared to placebo after 14 weeks, providing a new once-daily oral treatment option for those with this challenging condition.
Which Leading Players Are Enhancing Their Non-Radiographic Axial Spondyloarthritis Therapeutic Market Presence Worldwide?
Major companies operating in the non-radiographic axial spondyloarthritis therapeutic market are Pfizer Inc., Johnson & Johnson, Allergan plc, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Mochida Pharmaceutical Co. Ltd., Mereo BioPharma Group plc, Suzhou Zelgen Biopharmaceuticals Co. Ltd., Qyuns Therapeutics Co. Ltd.
Download The Full Report For Exclusive Market Findings:
How Is Non-Radiographic Axial Spondyloarthritis Therapeutic Market Demand Varying Across Different Regions?
North America was the largest region in the non-radiographic axial spondyloarthritis therapeutics market in 2024. The regions covered in the non-radiographic axial spondyloarthritis therapeutic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Non-Radiographic Axial Spondyloarthritis Therapeutic Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24627&type=smp
Browse Through More Reports Similar to the Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market 2025, By The Business Research Company
Generic Musculoskeletal Disorders Drugs Global Market Report 2025
Cervical Spondylosis Treatment Global Market Report 2025
Osteoarthritis Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model